Literature DB >> 3244621

Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats.

W L Chiou1, F H Hsu.   

Abstract

Unbound plasma clearances (CLu) in humans and rats of 15 extensively metabolized drugs (phenytoin, hexobarbital, pentobarbital, phenylbutazone, warfarin, tolbutamide, valproate, phenobarbital, amobarbital, quinidine, chlorpromazine, propranolol, pentazocin, antipyrine, and diazepam), studied earlier by Sawada et al. (J. Pharmacokin, Biopharm. 13:477-491, 1985), were calculated. It was found that the ratio of CLu per square meter of body surface area between human and rat ranged from 0.38 for pentobarbital to 2.34 for tolbutamide, with a mean ratio of 1.07. When body weight (BW) was used for correlation, the mean CLu was proportional to BW 0.657 +/- 0.0935. A rationale for the above empirical findings is postulated. The present study seems to indicate the existence of a general similarity or predictability in the CLu of drugs between rats and humans. Low correlations were generally obtained when total (bound and unbound) plasma clearances were used for comparison.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3244621     DOI: 10.1023/a:1015935206569

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

Review 1.  What does the power function reveal about structure and function in animals of different size?

Authors:  A A Heusner
Journal:  Annu Rev Physiol       Date:  1987       Impact factor: 19.318

2.  Scaling of standard energy metabolism in mammals: I. Neglect of circadian rhythms.

Authors:  J Prothero
Journal:  J Theor Biol       Date:  1984-01-07       Impact factor: 2.691

Review 3.  Pharmacokinetics and toxicity testing.

Authors:  B Clark; D A Smith
Journal:  Crit Rev Toxicol       Date:  1984       Impact factor: 5.635

4.  Energy metabolism and body size. I. Is the 0.75 mass exponent of Kleiber's equation a statistical artifact?

Authors:  A A Heusner
Journal:  Respir Physiol       Date:  1982-04

5.  The physiological significance of total body clearance in pharmacokinetic studies.

Authors:  W L Chiou
Journal:  J Clin Hosp Pharm       Date:  1982-03

Review 6.  Comparative drug metabolism.

Authors:  L B Mellett
Journal:  Prog Drug Res       Date:  1969

7.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

8.  Species similarities in pharmacokinetics.

Authors:  R L Dedrick; K B Bischoff
Journal:  Fed Proc       Date:  1980-01

9.  Albumin as a potential membrane transport barrier for hepatic clearance of diazepam studied by a universal organ clearance approach.

Authors:  W L Chiou
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1987-04

Review 10.  Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1985-10
View more
  4 in total

1.  Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model.

Authors:  S M Chung; E J Park; S M Swanson; T C Wu; W L Chiou
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

Review 2.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 3.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

4.  Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66.

Authors:  W L Chiou; G Robbie; S M Chung; T C Wu; C Ma
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.